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Abstract
Summary A randomized, double-blind, placebo-controlled
study assessed the efficacy of acetaminophen or fluvastatin
in preventing post-dose symptoms (increases in body
temperature or use of rescue medication) following a single
infusion of the intravenous (IV) bisphosphonate zoledronic
acid (ZOL). Acetaminophen, but not fluvastatin, significantly
reduced the incidence and severity of post-dose symptoms.
Introduction Transient symptoms including myalgia and py-
rexiahavebeenreportedpost-infusionofIVbisphosphonates,
typically starting the day after infusion and resolving within
several days. The cause is unknown but may be related to
transient cytokine elevations.Statins’potentialtoblockrelease
of these cytokines has been hypothesized. This study was
aimed to evaluate efficacy of acetaminophen and fluvastatin in
preventing/reducing post-dosesymptomsfollowingZOL 5mg
infusion.
Methods Randomized, double-blind, placebo-controlled
study of efficacy of acetaminophen or fluvastatin in
preventing increases in body temperature or use of rescue
medication (ibuprofen) following a single ZOL infusion.
Bisphosphonate-naive postmenopausal women with low
bone mass (N=793) were randomized into three treatment
groups and given 650 mg acetaminophen or 80 mg
fluvastatin or placebo 45 min before ZOL infusion. The
acetaminophen group continued taking 650 mg acetamin-
ophen every 6 h over the next 3 days, and the other two
groups took matching placebo according to the same
schedule. Subjects recorded body temperature, symptoms
in a diary. Inflammatory cytokines and C-reactive protein
(CRP) were measured at baseline, 24, and 72 h in a study
subset.
Results Acetaminophen four times/day significantly reduced
the incidence and severity of post-dose symptoms following
ZOL infusion. Single-dose fluvastatin 80 mg prior to ZOL
infusion did not prevent/reduce post-dose symptoms.
Cytokine levels increased by 24 h and returned towards
baseline by 72 h, similar to the pattern for post-infusion
symptoms. CRP levels increased from baseline to 72 h.
Conclusions Acetaminophen four times/day for 3 days
significantly reduced the incidence and severity of post-dose
symptoms following ZOL infusion.
Keywords Cytokines.Fluvastatin.Inflammatory
biomarkers.Osteoporosis.Post-dose symptoms.
Zoledronic acid
Introduction
Zoledronic acid (ZOL) is a nitrogen-containing intravenous
(IV) bisphosphonate that is approved for the treatment and
prevention of postmenopausal osteoporosis, for increasing
bone mass in men with osteoporosis, and for treatment and
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DOI 10.1007/s00198-010-1448-2prevention of glucocorticoid-induced osteoporosis. In a
placebo-controlled clinical trial of postmenopausal women
with osteoporosis (Health Outcomes and Reduced Incidence
with Zoledronic Acid Once Yearly [HORIZON]—Pivotal
Fracture Trial), once-yearly infusions of ZOL 5 mg signifi-
cantly reduced the risk of morphometric vertebral fracture by
70% (p<0.0001) and of hip fracture by 41% (p=0.002) over
36 months [1]. A subsequent placebo-controlled trial
(HORIZON-Recurrent Fracture Trial) demonstrated that an
annual infusion of ZOL after a recent low-trauma hip
fracture significantly reduced the incidence of clinical
fractures by 35% (p=0.001) compared with placebo [2].
The most common adverse events (AEs) associated with
ZOL are transient post-dose symptoms (also referred to as
an acute phase response) consisting of fever, myalgia,
arthralgia, headache, and flu-like symptoms [1]. These
symptoms may occur following initial treatment with
IV bisphosphonates; however, the incidence decreases
substantially with subsequent treatments [1, 3]. In the
HORIZON-Pivotal Fracture Trial, the proportion of patients
experiencing any of the five most common post-dose
symptoms decreased from 32% after the first dose to 7% after
the second annual dose and to 3% after the third annual dose
[1]. Post-dose symptoms are generally mild to moderate in
severity, and most resolve within 3 days, but some may last
for 7–14 days [3, 4]. Treatment with analgesics has been
reported to mitigate symptoms [3].
The mechanism for the acute phase response appears to
be associated with the transient release of inflammatory
cytokines (e.g., interleukin-6 [IL-6], tumor necrosis factor
alpha [TNF-α]) from gamma delta T-cells [5, 6]. Isopentenyl
pyrophosphate (IPP) is a known potent activator of gamma
delta T-cells [7–9]. ZOL inhibits osteoclast-mediated bone
resorption by blocking farnesyl pyrophosphate synthase
(FPS), a key enzyme in the mevalonate pathway [10, 11].
Blockade of FPS, in turn, results in increased levels of IPP in
monocytes [7]. It is believed that the acute phase response
following ZOL infusion occurs as a result of IPP-induced T-
cell activation and the subsequent release of inflammatory
mediators.
Statins are commonly used cholesterol-lowering drugs that
act by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase, a precursor of IPP and cholesterol in
the mevalonate pathway. Inhibition of HMG-CoA reductase
therefore prevents the synthesis of IPP. In vitro, co-treatment
of blood mononuclear cells with a statin and a nitrogen-
containing bisphosphonate (N-BP) completely prevents
proliferation and activation of gamma delta T-cells
c a u s e db yN - B P s[ 12]. We therefore hypothesized that
co-administration of a statin with ZOL would have the
potential to reduce IPP accumulation in monocytes, prevent
proliferation and activation of gamma delta T-cells, and
decrease the subsequent acute phase response.
ZOL is infused over 15 min and then rapidly binds to
bone. Any drug that does not bind to bone is excreted by
the kidney within 24 h. Therefore, a sufficient blood level
of statin would need to be present in the circulation prior to
ZOL administration and during the subsequent 24 h in
order to determine whether the acute phase response could
be attenuated in humans.
Fluvastatin 80 mg immediate release formulation was
chosen as the statin regimen for this study because this dose
was approved for another indication (cholesterol-lowering)
and pharmacokinetic data indicated that the immediate
release formulation would provide high, rapid levels of
circulating drug. Fluvastatin was dosed approximately
45 min prior to ZOL infusion in order to allow time for
oral absorption and peak blood levels of fluvastatin at the
time of ZOL infusion. No additional doses of fluvastatin
were given in this study.
Here, we report findings from a randomized, double-
blind study that compared the effects of acetaminophen,
fluvastatin, and placebo on transient post-dose symptoms
and inflammatory biomarker levels following a single dose
of ZOL in postmenopausal women with low bone mass.
Our hypothesis was that both acetaminophen and fluvastatin
would reduce the incidence and severity of post-dose
symptoms—the former, based on its antipyretic and analgesic
properties, and the latter, based on the potential for inhibition
of cytokine release (as suggested by in vitro data [12]). We
further hypothesized that reduction in post-dose symptoms
would be linked with reductions in the levels of inflammatory
biomarkers.
Methods
Study design
We conducted a randomized, multicenter, double-blind,
placebo-controlled, double-dummy, parallel group study to
evaluate the efficacy and safety of acetaminophen or
fluvastatin (Lescol; R*,S*-(E)]-(±)-7-[3-(4-fluorophenyl)-1-
(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic
acid, monosodium salt; Novartis Pharma) in preventing
clinically significant increases in body temperature or use
of rescue medication (ibuprofen) following a single
infusion of ZOL (Reclast; [1-Hydroxy-2-imidazol-1-yl-
phosphonoethyl] phosphonic acid monohydrate; Novartis
Pharma). The study was conducted at 94 sites in the
USA between June and December 2007. It was approved
by appropriate institutional review boards and conducted
according to the International Conference on Harmoni-
sation of Technical Requirements for Registration of
Pharmaceuticals for Human Use, local guidelines, and
the ethical principles of the Declaration of Helsinki.
2338 Osteoporos Int (2011) 22:2337–2345Informed consent was obtained from each patient prior to
conducting any study procedures.
The study included a screening visit and a screening
period of up to 31 days, followed by a randomization/
infusion visit (Day 1), a 3-day treatment period, and a final
visit (14 to 21 days after the infusion). Patients were given
a bottle of tablets containing calcium (600 mg) and vitamin
D3 (400 mg) at the screening visit and were instructed to
take two tablets daily for the duration of the study. During
the screening period, patients were instructed to stop taking
acetaminophen, nonsteroidal anti-inflammatory drugs
(NSAIDs), glucocorticosteroids, and statin medications to
comply with the required washout interval.
Body temperature was measured orally at baseline.
Patients completed a symptom questionnaire and recorded
severity of baseline symptoms on a 100-mm visual analog
scale (VAS; 0 [no symptoms] to 100 [severe symptoms]).
The symptom questionnaire consisted of three questions
(severity of fever, severity of headache, and severity of
aches and pains), each rated on a four-point categorical
scale (0 [absent] to three [severe]). Study medication
(acetaminophen, fluvastatin, or placebo) was administered
45±15 min before ZOL administration. Rescue medication
(unblinded ibuprofen) was dispensed, and patients were
instructed to take ibuprofen in addition to study medication
if they experienced severe discomfort. During the 3-day
treatment period, patients completed the symptom ques-
tionnaire four times daily (morning, midday, evening, and
late evening) and then recorded their oral body temperature
prior to taking study medication (acetaminophen/matching
placebo). The VAS score was recorded once per day in the
late evening. At the final visit, patient diaries were collected
and patients returned used bottles and unused study and
rescue medication. AEs and clinical chemistry variables
were evaluated.
Patients in the exploratory inflammatory biomarker
subgroup had their first blood sample drawn on Day 1
prior to ingesting their blinded study medications. Addi-
tional blood samples were collected at 24±2 and 72±2 h
after ZOL infusion. Blood samples were processed by
Quintiles Transnational (Durham, NC), and highly sensitive
serum biomarker assays capable of measuring low normal
levels were performed by Pacific Biomarkers of Seattle,
WA (IL-6 and TNF-alpha: R&D Systems, Minneapolis,
MN; interferon [IFN]-gamma: Meso Scale Discovery,
Gaithersburg, MD; highly sensitive CRP [hs-CRP]: Roche
Diagnostics North America, Indianapolis, IN).
The primary objective of this study was to demonstrate
the superiority of acetaminophen vs. placebo in preventing
clinically significant increases in body temperature or use
of rescue medication during 3 days following ZOL
infusion. Secondary objectives included assessment of
whether fluvastatin was superior to placebo in preventing
clinically significant increases in body temperature measured
orally or use of rescue medication.
Patients
Postmenopausal women aged between 45 and 79 years
with a clinical indication for bisphosphonate treatment
for osteopenia or osteoporosis and a documented spine or
hip bone mineral density dual-energy X-ray absorptiometry
T-score of -1.5 or less were eligible for participation in this
study. Women who had used IV bisphosphonates or taken
oral bisphosphonates for more than 8 weeks or within
6 months of screening were excluded. Other exclusion
criteria included the use of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins)
or systemic IV or oral corticosteroids within 7 days prior
to randomization; the use of acetaminophen, NSAIDs,
tranquilizers, muscle relaxants, raloxifene, or calcitonin
within 36 h of randomization; or the use of anticoagulant
therapy. Patients with proteinuria (urine dipstick ≥2+),
impaired creatinine clearance (<30 ml/min), or abnormal
serum calcium levels (>2.75 or <2.08 mmol/l) at
screening were not eligible for study participation.
Patients with an ongoing infection (including dental
infection) or planned oral surgery within 3 months of
randomization were also excluded.
Study medications
All patients received an infusion of ZOL 5 mg over at
least 15 min on Day 1. Patients were randomized to one
of three treatment groups. All oral study drugs were
double-blinded with matching placebo capsules. In
Group 1, 45 min prior to ZOL infusion, two capsules
of acetaminophen 325 mg were administered orally.
Subjects in this group continued to take two capsules
of acetaminophen four times daily for the next 3 days
a th o m e .I nG r o u p2 ,4 5m i np r i o rt oZ O Li n f u s i o n ,t w o
capsules of immediate-release fluvastatin 40 mg were
administered orally. Fluvastatin was administered only
once, on Day 1, prior to ZOL infusion. Subjects in the
fluvastatin group were provided with placebo capsules
(matching acetaminophen) and took two capsules four
times daily for the next 3 days at home. In Group 3,
subjects received placebo 45 min prior to ZOL infusion
and continued to take two capsules of placebo (matching
acetaminophen) four times daily for the next 3 days at
home.
Patients in this study were also provided with calcium
600 mg plus vitamin D3 400 IU (one tablet twice daily).
Open-labelrescuemedication(ibuprofen200mgtabletsevery
4 to 6 h, not to exceed eight tablets in a 24-h period) could be
taken if the patient had an oral body temperature ≥38.9°C
Osteoporos Int (2011) 22:2337–2345 2339(102°F) and/or severe symptoms of fever, headache, myalgia,
or arthralgia.
Study personnel observed each patient ingest the first
dose of study medication and receive the ZOL infusion.
Patient diaries and unused medication were used to assess
compliance during the remainder of the study. Patients
recorded the dose, date, and time of study and rescue
medication use in diaries and returned used bottles and
unused study and rescue medication at the final visit.
Efficacy and safety variables
The primary efficacy variable in this study was the
proportion of patients who had a clinically significant
increase in oral body temperature (≥1°C from baseline
and ≥38.5°C overall) or used rescue medication at least
once during the 3-day period following ZOL infusion.
Oral body temperature was measured at baseline prior to
ZOL infusion using a digital thermometer (Welch Allyn
Sure Temp), which was provided to each patient for the
duration of the study. Patients were trained to take two
temperature assessments within 10 min of each other four
times per day for 3 days. Temperature assessments were
conducted after completing VAS and symptom questionnaires
and prior to taking any oral study medication. Patients
recorded the time and number of tablets of rescue medication
taken, if any, in their diaries.
Secondary efficacy variables included the proportion of
patients with a clinically significant increase in body
temperature and the proportion of patients who used rescue
medication. Change from baseline in mean temperature,
change from baseline in symptom VAS, major increases in
severity of symptoms (an increase from baseline of a
minimum of two units on the symptom questionnaire at
least once during the 3 days immediately following ZOL
infusion), and severe symptoms (reported at least once)
were also examined. Levels of inflammatory biomarkers
(IL-6, TNF-alpha, IFN-gamma, hs-CRP) in a subgroup of
patients were exploratory variables.
AEs were monitored and recorded throughout the study.
Physical examinations and evaluations of vital signs and
clinical chemistry were performed at the screening and final
visits.
Statistical analyses
Statistical analyses were performed by Rho (Cary, NC)
using SAS statistical software (version 9.1). Assuming that
the proportion of patients with a clinically significant
increase in oral body temperature was 33% in the placebo
group and 19% in the acetaminophen group and that the
dropout rate was 10%, the study would require 243 patients
per group (total of 729 patients) to have at least 90% power
to detect a difference between the two groups. This
calculation used a two-group continuity-corrected Chi-
square test with a two-sided significance level of 0.05.
Theprimaryefficacyvariable(clinicallysignificantincrease
in temperature or rescue medication) was analyzed using a
logisticregressionmodelwithtreatmentandbaselineoralbody
temperature (mean of two temperatures recorded at baseline)
as explanatory variables; odds ratios (OR) for pairwise
treatment comparisons, 95% confidence intervals (CI) for
OR, and p values are presented. Two binary secondary
efficacy variables (clinically significant increase in tempera-
ture, rescue medication use) were similarly analyzed.
Change from baseline in symptom VAS was analyzed by
an analysis of covariance model with treatment and
baseline VAS as explanatory variables. Between-treatment
comparisons of proportions of patients with major increases
in severity of symptoms and severe symptoms (reported at
least once) were made based on pairwise Chi-square tests.
Correlations between changes in inflammatory biomarkers
and changes in temperature or symptoms were evaluated by
use of Pearson and Spearman correlation coefficients.
Results
Patients
Of 1,008 patients screened, 793 were randomized, and 779
completed the study. All analyses were conducted on the 793
randomized patients. The primary reason for withdrawal was
AEs (ten of 14 withdrawals). Overall withdrawals and
withdrawals due to AEs occurred at comparable rates in the
three treatment groups. Treatment groups were generally well
matched with respect to baseline characteristics. Overall,
90.5% of the study population was Caucasian, the mean age
was 61.7 years, and the mean number of menopausal years
was 15.7. In the subgroup of patients with inflammatory
biomarker data (n=96, placebo 33 patients, acetaminophen
33 patients, fluvastatin 30 patients), demographic and
background characteristics were similar to those in the ITT
population, and the treatment groups remained well matched.
Compliance was excellent and well balanced across treat-
ment groups. There were no compliance issues with respect
to fluvastatin, as the sole dose was administered by study
personnel; for acetaminophen and acetaminophen-matching
placebo, the mean number of capsules taken ranged from
21.2 to 21.5 (out of 24).
Efficacy outcomes
Following a single infusion of ZOL 5 mg, acetaminophen
was found to be superior to placebo in preventing or
reducing post-dose symptoms over the subsequent 3-day
2340 Osteoporos Int (2011) 22:2337–2345period. Clinically significant increases in oral body tem-
perature or use of rescue medication occurred in 60.7%
(162) of 267 patients in the placebo group vs. 39.8% (105
of 264 patients) in the acetaminophen group (p<0.001;
Fig. 1). In contrast, no effect was observed from a single
dose of fluvastatin taken 45 min prior to the ZOL infusion,
with a total of 61.8% of patients (162 of 262) having
increased temperature or using rescue medication. Sub-
group analyses showed that all age groups (45–55 years,
56–64 years, and 65 years and older) experienced significant
benefits from acetaminophen.
Acetaminophen also produced significant benefits with
respect to secondary efficacy variables. Compared with
placebo, acetaminophen significantly decreased the propor-
tionofpatientswithincreasedbodytemperature,ofthose who
used rescue medication, of those who experienced a major
increaseinseverityofsymptoms,andofthosewhoreportedat
least one episode of severe symptoms. Fluvastatin did not
significantly affect any symptom variables (Table 1).
Compared with patients in the fluvastatin and placebo
groups, patients in the acetaminophen group had a lower
peak increase in body temperature and an earlier return to
baseline levels (Fig. 2a). For each treatment group, the
largest mean increase in temperature occurred between 24
and 48 h following ZOL infusion, and the peak value was
recorded at the Day 2 evening measurement. The symptom
VAS (recorded once each evening) followed a similar
pattern (Fig. 2b), with peak values on Day 2, and the mean
difference between placebo and acetaminophen was statis-
tically significant at all time points (p<0.05). In contrast, no
significant differences were observed between placebo and
fluvastatin.
Inflammatory biomarkers
Serum levels of inflammatory biomarkers were evaluated in
96 patients at baseline, 24 h, and 72 h. Baseline concen-
trations of IL-6, IFN-gamma, TNF-alpha, and hs-CRP were
generally comparable across treatment groups (Table 2).
The pattern of elevations of all four inflammatory bio-
markers showed an increase in levels by 24 h after infusion
(Day 2, morning; Table 2; Fig. 3a–d); elevations in body
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Fig. 1 Proportion of patients with fever (clinically significant increase
in oral body temperature [1°C or more from baseline and 38.5°C or
more overall]) or use of at least one dose of rescue medication during
the 3-day period following IV zoledronic acid infusion (intent-to-treat
population). Cross-hatching indicates proportion of patients in each
group with one or more episodes of fever recorded in the patient diary
(no p values shown for the latter comparisons). acet acetaminophen,
fluv fluvastatin, plac placebo
Table 1 Clinically significant increase in oral body temperature, rescue medication use, worsening symptoms, and severe symptoms during the 3-day
period following IV zoledronic acid infusion
Variables PLAC (N=267) ACET (N=264) FLUV (N=262)
Number Percentage (%) Number Percentage (%) Number Percentage (%)
Clinically significant increase in temperature
a 28 10.5 13 4.9
b 30 11.5
Use of rescue medication 153 57.3 102 38.6
c 156 59.5
Major increase in severity of symptoms
Feeling feverish 105 39.3 62 23.5
c 104 39.7
Headache 104 39.0 67 25.4
c 115 43.9
Aches and pains 127 47.6 89 33.7
c 121 46.2
Severe symptoms (reported at least once)
Feeling feverish 36 13.5 20 7.6
b 38 14.5
Headache 42 15.7 18 6.8
c 42 16.0
Aches and pains 81 30.3 56 21.2
b 79 30.2
ACET acetaminophen, FLUV fluvastatin, PLAC placebo
a1°C or more from baseline and 38.5°C or more overall
bp<0.05 vs. placebo
cp≤0.001 vs. placebo
Osteoporos Int (2011) 22:2337–2345 2341temperature were also reported on the morning of Day 2
(Fig. 2a). Levels of all three cytokines (IL-6, TNF-alpha,
and IFN-gamma) returned to near baseline by 72 h, by
which point most of the temperature elevations had
declined. The biomarker, CRP, continued to rise from
baseline to 72 h.
Inflammatory biomarker changes were weakly correlated
with changes in body temperature and VAS scores. IL-6,
IFN-gamma, and hs-CRP levels were generally higher in
patients with a major increase in symptom severity (with
the exception of severe headaches). However, some
asymptomaticpatientsalsoexperienced biomarker elevations.
The use of acetaminophen appeared to attenuate increases in
IL-6 and IFN-gamma levels at 24 h in this treatment group
compared with those reported for the placebo and fluvastatin
groups (Fig. 3a, c).
Safety
In safety evaluations, post-dose symptoms were not counted
as AEs, since they were collected in patient diaries as
secondary outcomes. The most common AEs were musculo-
skeletal and connective tissue disorders, general disorders and
administration site conditions, and gastrointestinal disorders.
AEs occurred at comparable rates across treatment groups.
There were no deaths in the study. Five (0.6%) patients
reported six serious AEs (one [hypokalemia] in the placebo
group, two [syncope and pleuritic pain] in the acetaminophen
group, and three [convulsion, pyrexia, and uveitis] in the
fluvastatin group). Ten (1.3%) patients withdrew from
the study due to AEs (three in the placebo group, three
in the acetaminophen group, and four in the fluvastatin
group). There were no notable differences between
treatment groups in serious AEs or treatment withdrawals.
No clinically significant between-group differences were
observed in laboratory values or vital signs.
Discussion
Transient post-dose symptoms are the most frequently
reported AEs following ZOL infusions in postmenopausal
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Fig. 2 Change from baseline in a mean body temperature and b VAS
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Table 2 Serum levels of inflammatory biomarkers
PLAC (N=33) ACET (N=33) FLUV (N=30)
IL-6 (pg/ml): median (min, max)
a
Baseline 2.0 (1, 61) 2.1 (0, 31) 2.5 (0, 8)
24 h 14.5 (2, 154) 9.7 (2, 73) 14.8 (2, 79)
72 h 3.9 (1, 160) 2.8 (1, 56) 3.5 (2, 79)
TNF-alpha (pg/ml): median (min, max)
b
Baseline 1.9 (1, 5) 1.9 (1, 9) 1.8 (1, 7)
24 h 3.8 (1, 9) 3.7 (2, 11) 4.1 (2, 12)
72 h 2.6 (1, 7) 2.2 (0, 12) 3.8 (1, 9)
IFN-gamma (pg/ml): median (min, max)
c
Baseline 0.6 (1, 4) 0.6 (1, 4) 0.6 (1, 2)
24 h 75.5 (1, 363) 40.7 (1, 872) 98.2 (4, 3479)
72 h 2.0 (1, 24) 1.6 (1, 12) 3.1 (1, 10)
hs-CRP (mg/l): median (min, max)
d
Baseline 2.3 (0, 13) 2.3 (1, 8) 1.8 (0, 49)
24 h 8.0 (0, 81) 4.7 (1, 45) 7.8 (0, 77)
72 h 25.1 (0, 89) 19.3 (1, 133) 20.2 (0, 71)
ACET acetaminophen, FLUV fluvastatin, hs-CRP highly sensitive C-
reactive protein, PLAC placebo
aIL-6 (pg/ml) normal reference range: 0.51–4.92
bTNF-alpha (pg/ml) normal reference range: less than 1.86
cIFN-gamma (pg/ml) normal reference range: less than 1.9
dhs-CRP (mg/l) normal reference range: less than 3.0
2342 Osteoporos Int (2011) 22:2337–2345women [1]. These symptoms are believed to be caused by
the accumulation of IPP as a result of FPP blockade in the
mevalonate pathway, a key step in the inhibition of bone
resorption by ZOL [10]. Statins block an earlier stage of
this pathway and do not lead to IPP accumulation. In vitro,
pretreatment of peripheral blood mononuclear cells with a
statin followed by exposure of the cells to a bisphosphonate
prevents the bisphosphonate-induced release of inflammatory
cytokines including TNF-alpha and IFN-gamma [12].
In this trial, we evaluated the efficacy of acetaminophen
and fluvastatin in preventing or reducing post-dose symp-
toms following administration of a single infusion of ZOL
in bisphosphonate-naive postmenopausal women with low
bone mass. The primary objective of this study was met:
acetaminophen was significantly more effective than
placebo in reducing clinically significant increases in body
temperature or use of rescue medication. Acetaminophen
resulted in substantial reductions in the incidence and
severity of symptoms and was effective in all age groups. In
contrast, pretreatment with a single dose of immediate-
release fluvastatin given prior to ZOL infusion failed to
demonstrate a significant effect on post-dose symptoms in
any of the analyses conducted.
Exploratory analyses of inflammatory biomarkers in a
subsetofpatientsprovided insights intopotential mechanisms
for the manifestation of post-dose symptoms. The timing of
the maximum increases in levels of IL-6, TNF-alpha, and
IFN-gamma were generally similar to the timing of the
maximum increases in body temperature and VAS scores
(Figs. 2 and 3), with elevations occurring between baseline
and 24 h and levels returning to near baseline by 72 h.
Changes in CRP showed a different pattern, with levels
continuing to increase between 24 and 72 h. However, it
should be noted that CRP synthesis is upregulated by
inflammatory cytokines, including IL-6. Serum CRP levels
begin to increase as soon as the inflammatory stimuli ebb
and therefore may exhibit a later increase and slower decline
than cytokine levels [13].
IL-6, IFN-gamma, and CRP levels were generally higher
in patients with a major increase in symptom severity (with
the exception of severe headaches). However, both asymp-
tomatic and symptomatic patients experienced biomarker
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Fig. 3 Change from baseline
in serum levels of a IL-6, b
TNF-alpha, c IFN-gamma,
and d hs-CRP following IV
zoledronic acid infusion in a
subset of 96 patients receiving
treatment with placebo (plac),
acetaminophen (acet), or
fluvastatin (fluv). Measurements
were taken at baseline and at
24 and 72 h post-infusion.
hs-CRP highly sensitive
C-reactive protein, IFN
interferon, IL interleukin,
TNF tumor necrosis factor
Osteoporos Int (2011) 22:2337–2345 2343elevations, so the correlation between symptom severity
and biomarker levels was weak. Acetaminophen, but not
fluvastatin, attenuated increases in IL-6 and IFN-gamma
levels compared with placebo following ZOL infusion.
In this study, 39.3% of placebo-treated patients reported a
major increase in feeling feverish over the 3-day treatment
period (Table 1), compared with 9%–16% of patients in
previousZOLtrialswhospontaneouslyreportedpost-infusion
fever symptoms at the next office visit [1, 2]. In terms of
objective temperature measurements, 10.5% of placebo
patients in the current study experienced at least one clinically
significant elevation in oral body temperature (similar to the
percentage spontaneously reporting fever in previous ZOL
trials); however, 57.3% of patients took at least one dose of
ibuprofen, which may have lowered the maximum tempera-
ture increase. Regarding cytokine levels, our findings are in
partial agreement with other studies examining cytokine
profiles following IV bisphosphonate infusions. As in the
studies by Thiébaud et al. [5] and Dicuonzo et al. [6], we
found that the pattern of IL-6 elevations closely mirrored the
time course of post-dose symptoms and that IL-6 increases
were greater in patients with symptoms. However, our data
support a potential role for IFN-gamma in mediating post-
dose symptoms, whereas the study by Dicuonzo and
colleagues [6] did not. Differences in study populations or
use of more sensitive biomarker assays in our study may
help to explain this discrepancy.
CRP levels were increased at 72 h in the current study,
and no additional measurements were available at later time
points. However, data from a study by Michael Rogers and
colleagues showed that elevations in CRP levels after a
ZOL 5-mg infusion were back to baseline levels when
measured 4 weeks post-infusion (Keith Thompson and
Michael Rogers, personal communication).
Although pretreatment with statins has been shown to
block bisphosphonate-induced cytokine release in vitro
[12], this clinical study did not demonstrate any benefit of
dosing with fluvastatin prior to ZOL infusion. Our findings
are consistent with those of a recent study by Srivastava
and colleagues [14] in which atorvastatin 10 mg was
administered to children with metabolic bone diseases
receiving IV bisphosphonate treatment. Atorvastatin did
not result in significant reductions in pain, rescue
medication use, or CRP levels, leading the authors to
conclude that this agent was not effective in modulating
bisphosphonate-induced post-dose responses. Data from
clinical studies thus suggest that statins do not reduce the
incidence of post-infusion symptoms.
Our study implicates IL-6 and IFN-gamma in the
induction of post-dose symptoms, as both biomarkers
showed marked elevations following ZOL infusion and
their temporal patterns closely mirrored changes in body
temperature and VAS symptom scores. In addition, acet-
aminophen reduced symptom scores and resulted in lower
peak levels of these cytokines at 24 h.
Limitations of the current study include the 72-h duration
of inflammatory biomarker monitoring; additional data after
72h may havebeenusefultodocument ongoing changes in
CRP and determine when levels returned to baseline
values. Moreover, we did not know the optimal dose of
fluvastatin, or the optimal timing of its administration for
use in this setting.
We conclude that acetaminophen is effective in signif-
icantly reducing the incidence and severity of post-dose
symptoms following ZOL infusion. Exploratory analyses of
inflammatory biomarkers suggest that acetaminophen-
mediated reductions in IL-6 and IFN-gamma levels may
help to explain the effect of this agent on post-dose
symptoms. In contrast to acetaminophen, pretreatment with
a single dose of fluvastatin did not show any benefit in
mitigating post-dose symptoms. Based on these data, we
encourage clinicians to consider the use of acetaminophen
650 mg four times daily for 3 days for the reduction of
post-dose symptoms following ZOL infusions.
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